Russo Cristina, Colaianni Valeria, Ielo Giuseppe, Valle Maria Stella, Spicuzza Lucia, Malaguarnera Lucia
Section of Pathology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Biomedicines. 2022 Jun 6;10(6):1337. doi: 10.3390/biomedicines10061337.
There is a fine balance in maintaining healthy microbiota composition, and its alterations due to genetic, lifestyle, and environmental factors can lead to the onset of respiratory dysfunctions such as chronic obstructive pulmonary disease (COPD). The relationship between lung microbiota and COPD is currently under study. Little is known about the role of the microbiota in patients with stable or exacerbated COPD. Inflammation in COPD disorders appears to be characterised by dysbiosis, reduced lung activity, and an imbalance between the innate and adaptive immune systems. Lung microbiota intervention could ameliorate these disorders. The microbiota's anti-inflammatory action could be decisive in the onset of pathologies. In this review, we highlight the feedback loop between microbiota dysfunction, immune response, inflammation, and lung damage in relation to COPD status in order to encourage the development of innovative therapeutic goals for the prevention and management of this disease.
维持健康的微生物群组成存在微妙的平衡,而由于遗传、生活方式和环境因素导致的微生物群改变会引发呼吸功能障碍,如慢性阻塞性肺疾病(COPD)。目前正在研究肺部微生物群与COPD之间的关系。对于稳定期或加重期COPD患者中微生物群的作用知之甚少。COPD疾病中的炎症似乎以生态失调、肺活动降低以及先天性和适应性免疫系统之间的失衡为特征。肺部微生物群干预可能改善这些疾病。微生物群的抗炎作用在疾病的发生中可能起决定性作用。在这篇综述中,我们强调了与COPD状态相关的微生物群功能障碍、免疫反应、炎症和肺损伤之间的反馈回路,以促进针对该疾病预防和管理的创新治疗目标的发展。